MPLT
MapLight Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
MapLight Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Fund move
Fund move
No thesis.
MapLight Therapeutics, Inc.
7.66
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | NovoNovo | $132.1M | 14.03% | 0.00% | |
| 2 | Fcpm III Services B.V.Fcpm III Services B.V. | $115.6M | 12.28% | 0.00% | |
| 3 | T. Rowe Price Investment ManagementT. Rowe Price | $99.7M | 10.58% | −0.72% | |
| 4 | Goldman Sachs GroupGoldman Sachs | $69.8M | 7.41% | −2.33% | |
| 5 | T. Rowe Price AssociatesT. Rowe Price | $51.0M | 5.41% | +1162.50% | |
| 6 | BlackRockBlackRockindex-like | $36.7M | 3.90% | −23.48% | |
| 7 | Nan Fung Group HoldingsNan Fung | $34.8M | 3.70% | 0.00% | |
| 8 | 5AM Venture Management5AM Venture | $34.0M | 3.61% | 0.00% | |
| 9 | SanofiSanofi | $32.7M | 3.47% | 0.00% | |
| 10 | State StreetState Streetindex-like | $30.5M | 3.24% | +151.29% | |
| 11 | FMRFMR | $29.5M | 3.13% | +302.71% | |
| 12 | Vanguard Capital ManagementVanguardindex-like | $28.1M | 2.98% | +8.94% | |
| 13 | Blue Owl Capital HoldingsBlue Owl Capital | $26.2M | 2.78% | −27.44% | |
| 14 | Paradigm Biocapital AdvisorsParadigm Biocapital | $24.6M | 2.61% | new | |
| 15 | Pivotal bioVenture Partners Investment AdvisorPivotal bioVenture Partners Investment Advisor | $21.9M | 2.33% | 0.00% | |
| 16 | Velan Capital Investment ManagementVelan Capital | $17.7M | 1.88% | 0.00% | |
| 17 | SirenSiren | $16.1M | 1.71% | 0.00% | |
| 18 | Capital World InvestorsCapital World Investors | $14.9M | 1.58% | new | |
| 19 | Geode Capital ManagementGeodeindex-like | $14.4M | 1.53% | −16.45% | |
| 20 | Baker Bros. AdvisorsBaker Bros. | $13.1M | 1.39% | 0.00% | |
| 21 | DAFNA Capital ManagementDAFNA | $6.1M | 0.65% | 0.00% | |
| 22 | BNP Paribas Investment PartnersBNP Paribas Investment Partners | $6.1M | 0.65% | −36.19% | |
| 23 | Freestone Grove PartnersFreestone Grove Partners | $6.1M | 0.64% | −46.20% | |
| 24 | Charles Schwab Investment ManagementCharles Schwabindex-like | $4.9M | 0.52% | −15.10% | |
| 25 | Millennium ManagementMillennium | $4.6M | 0.49% | new |
105 managers report $941.9M of MapLight Therapeutics on form 13F for the quarter ended Jun 30 '26. 15 of them hold 80% of it; Novo is largest at 14.03%.
No implied move.
No implied move.
Expected move
No implied move.